Difference between revisions of "Team:ETH Zurich"
| Line 46: | Line 46: | ||
</script> | </script> | ||
| − | |||
| + | <style> | ||
body { | body { | ||
| Line 88: | Line 88: | ||
font-weight: 900; | font-weight: 900; | ||
} | } | ||
| − | |||
| − | |||
| − | |||
</style> | </style> | ||
</head> | </head> | ||
| + | |||
<body> | <body> | ||
| − | |||
<div class="title"> | <div class="title"> | ||
| Line 106: | Line 103: | ||
<center> | <center> | ||
</div> | </div> | ||
| − | |||
| Line 118: | Line 114: | ||
<div class="content"> | <div class="content"> | ||
<div id="start"> | <div id="start"> | ||
| − | Cancer kills over 8 million people every year. That's the entire population of Switzerland! <br><br> | + | Cancer kills over 8 million people every year. That's the entire population of Switzerland! <br><br> |
| − | We need more specific therapies because current approaches result in many side-effects.<br> | + | We need more specific therapies because current approaches result in many side-effects.<br> |
| − | That's why we created CATE: Cancer-Targeting E. coli. | + | That's why we created CATE: Cancer-Targeting E. coli. |
| − | <br> | + | <br> |
| − | <br> | + | <br> |
| + | <a href="https://2017.igem.org/Team:ETH_Zurich/Background" class="more">Learn more</a> | ||
| − | + | <img src="https://static.igem.org/mediawiki/2017/9/99/T--ETH_Zurich--CH.png" class="CH" width="500px" align="right"> | |
| − | + | ||
| − | <img src="https://static.igem.org/mediawiki/2017/9/99/T--ETH_Zurich--CH.png" class="CH" width="500px" align="right"> | + | |
</div> | </div> | ||
<div id="second"> | <div id="second"> | ||
| − | <img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="Ec" width="400px" align="left"> | + | <img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="Ec" width="400px" align="left"> |
| + | </div> | ||
| + | |||
| + | CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors.<br><br> We are engineering E. coli Nissle to carry a MRI | ||
| + | contrast and a cytotoxic agent so it can deliver both components to tumor sites. | ||
| + | <br> | ||
| + | <br> | ||
| + | <a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Project description</a> | ||
</div> | </div> | ||
| − | |||
| − | |||
| − | |||
| − | |||
Revision as of 14:43, 7 October 2017
Cancer kills over 8 million people every year. That's the entire population of Switzerland!
We need more specific therapies because current approaches result in many side-effects.
That's why we created CATE: Cancer-Targeting E. coli.
Learn more
We need more specific therapies because current approaches result in many side-effects.
That's why we created CATE: Cancer-Targeting E. coli.
Learn more
We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.
Project description
